Split availability: semaglutide is available through a licensed clinician; cagrilintide is investigational; we don't offer a CagriSema blend.
CagriSema stack
CagriSema pairs a GLP-1 (semaglutide) with an amylin analog (cagrilintide) for complementary appetite signaling. Unlike most stacks, this one has real pharmaceutical trial data behind the combination.
Last reviewed June 16, 2026.
The honest answer
CagriSema pairs a GLP-1 (semaglutide) with an amylin analog (cagrilintide) to hit two complementary satiety pathways. It's the rare stack with real combination data, a pharma-run clinical program studies the blend as a single developed product. The catch: cagrilintide isn't independently available, and a do-it-yourself mix is not the trial product.
- CagriSema is the only one of these stacks with combination data from a pharma-run clinical program.
- Semaglutide and cagrilintide act on complementary satiety pathways.
- Cagrilintide is investigational and not independently available.
- A do-it-yourself ‘blend’ is not the trial product, trial results don't transfer to a grey-market mix.
Go deeper
The concept layers GLP-1 satiety (semaglutide) with amylin satiety (cagrilintide) so two appetite pathways are engaged at once. What makes CagriSema unusual is that a pharmaceutical program is testing exactly that combination as one product, so the rationale has trial data behind it. That data belongs to the developed product, not to a compounded or grey-market blend.
We don't offer a CagriSema blend. If a GLP-1 plan fits your goals, a licensed clinician maps it, only what's legitimately available.
CagriSema is the validated end of the spectrum, a real trial program. Community blends like ‘Reta + Cag’ sit at the other end: zero combination data, both molecules investigational.
| Combination | Trial data | What's available |
|---|---|---|
| CagriSemasemaglutide + cagrilintide | Pharma-run combination program (real trial data) | Semaglutide available via a clinician; cagrilintide investigational; no blend offered |
| Reta + Cagrilintide (‘LEAN’)retatrutide + cagrilintide | None, community-derived | Both investigational; zero combination-trial data |
Status & access
Semaglutide is available through a licensed clinician; cagrilintide is investigational and not independently available. Compounded semaglutide is not FDA-approved; branded GLP-1s are. We route you to a metabolic plan, only what's legitimately available, not a CagriSema blend.
Compounded medications are prepared for an individual patient and are not FDA-approved. Removal from FDA Category 2 (April 2026) is not approval and not 503A Bulks-List eligibility. PCAC is advisory, a favorable vote leads to rulemaking, not instant availability.
We don't offer a CagriSema blend. If a GLP-1 plan fits your goals, a licensed clinician maps it, only what's legitimately available.
Questions, answered first
What is CagriSema?
CagriSema is a combination of semaglutide (a GLP-1) and cagrilintide (an amylin analog) being developed as a single weight-management product. It's the one combination in this set with real pharmaceutical trial data, but as a finished drug in development, not a blend you can assemble or buy today.
Is CagriSema available in 2026?
Not as a blend. Semaglutide is available through a licensed clinician (branded GLP-1s are FDA-approved; compounded semaglutide is not). Cagrilintide is investigational and not independently available, and we don't offer a CagriSema mix, we route to a clinician-mapped metabolic plan instead.
CagriSema vs semaglutide alone?
CagriSema adds an amylin analog (cagrilintide) to semaglutide to engage a second satiety pathway, and its pharma program is studying whether that combination outperforms semaglutide alone. Today, the legitimately available option is a clinician-mapped GLP-1 plan; the combination product and cagrilintide on its own are not available.